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ABSTRACT 
Objectives: The development of endometriosis is associated with changes in the expression of genes encoding the 
3β-hydroxysteroid dehydrogenase type II (HSD3B2) and 17β-hydroxysteroid dehydrogenase type II (HSD17B2), estrogen 
receptors 1 (ESR1) and 2 (ESR2) and the androgen receptor (AR). However, little is known about the expression of HSD3B2, 
HSD17B1, HSD17B2, ESR1 ESR2 and AR during the endometrial phases in eutopic endometrium from infertile women with 
endometriosis. 
Material and methods: Using RT-qPCR analysis, we assessed the expression of the studied genes in the follicular and luteal 
phases in eutopic endometrium from fertile women (n = 17) and infertile women (n = 35) with endometriosis. 
Results: In the mid-follicular eutopic endometrium, we observed a significant increase in HSD3B2 transcript levels in all 
infertile women with endometriosis (p = 0.003), in infertile women with stage I/II endometriosis (p = 0.008) and in infertile 
women with stage III/IV endometriosis (p = 0.009) compared to all fertile women. There was a significant increase in ESR1 tran-
scripts in all infertile women with endometriosis (p = 0.008) and in infertile women with stage I/II endometriosis (p = 0.019) 
and in infertile women with stage III/IV endometriosis (p = 0.023) compared to all fertile women. In the mid-luteal eutopic 
endometrium, we did not observe significant differences in HSD3B2, HSD17B1, HSD17B2, ESR1, ESR2 and AR transcripts 
between infertile women with endometriosis and fertile women. 
Conclusions: Observed significant increase in HSD3B2 and ESR1 transcripts in follicular eutopic endometrium from infer-
tile women with endometriosis may be related to abnormal biological effect of E2 in endometrium, further affecting the 
development of human embryos.
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INTRODUCTION
Endometriosis is a disease characterized by the existen-
ce of functional ectopic endometrium outside the uterine 
cavity that affects 6–10% of women of reproductive age [1]. 
Three main etiopathogenic hypotheses regarding the deve-
lopment of endometriosis have been suggested [2, 3]. The 
most widely accepted includes the retrograde shedding 
of endometriotic cells during menstruation inside the ab-
dominal cavity, which results in a persistent inflammatory 
response [2, 3]. Other theories explaining the development 
of these lesions include the coelomic metaplasia theory, 
which relates to the formation of endometrial tissue from 
the differentiation of mesothelium cells [2, 3]. It has also 
been suggested that there is an embryonic origin of endo-
metriosis [2, 3]. Depending on the severity of endometriosis, 
it can be subdivided into peritoneal, ovarian and deep le-
sions, which spread in the vagina, bowels, bladder or ureter 
[4, 5]. Endometriosis is a complex disorder resulting from 
interactions between genetic and environmental factors 
[6, 7]. The development of endometriosis is related to the 
abnormal expression of genes encoding proteins involved 
in vascular and tissue remodelling, enzymes involved in 
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glucose homeostasis and proteins affecting sex hormone 
activity [6, 8]. Endometriosis is also characterized by epige-
netic disorders associated with the hypermethylation and 
hypomethylation of some gene promotors, modifications 
of the histone code and abnormal expression of various 
miRNAs involved in the pathogenesis of this disease [9]. 
However, the exact molecular mechanism accounting 
for the development of endometriosis and related infertility 
remains unclear [3]. To date, the expression of several genes 
involved in the metabolism and action of steroids have been 
demonstrated as being involved in endometriosis [10–13]. 
They include genes encoding 3β-hydroxysteroid dehydro-
genase (HSD3B2) (OMIM * 613890), 17β-hydroxysteroid de-
hydrogenase type I (HSD17B1) (OMIM * 109684), 17β-hydro- 
xysteroid dehydrogenase type II (HSD17B2) (OMIM * 109685), 
estrogen receptor 1 (ESR1) (OMIM +133430), estrogen recep-
tor 2 (ESR2) (OMIM * 601663), and androgen receptor (AR) 
(OMIM * 313700). However, little is known about HSD3B2, 
HSD17B1, HSD17B2, ESR1, ESR2 and AR expression in luteal 
and follicular eutopic endometrium in infertile women with 
endometriosis. Therefore, we assessed the expression of 
these genes during the follicular and luteal phases in euto-
pic endometrium from infertile women with endometriosis 
and fertile women. 
MATERIAL AND METHODS
Patients and controls
Data from fertile women and infertile women with en-
dometriosis were randomly collected from the Gynaecologic 
and Obstetrical University Hospital, Division of Reproduction 
in Poznan, Poland (Tab. 1). The control group comprised 
fertile women who suffered from chronic pelvic pain, dia-
gnosed as having varicose veins in the pelvic floor without 
any pelvic abnormalities and without a history of infertility. 
The varicose veins in the pelvic floor were diagnosed by 
ultrasound method and confirmed via laparoscopy. The 
criteria for the sonographic diagnosis of varices included 
(1) the visualization of dilated ovarian veins greater 
than 4 mm in diameter, (2) dilated tortuous arcuate veins 
in the myometrium that communicate bilaterally with the 
pelvic varicose veins, (3) slow blood flow (less than 3 cen-
timeters per second), and reversed caudal or retrograde 
venous blood flow particularly in the left ovarian vein [14]. 
The inclusion and exclusion criteria for the women wi-
thout endometriosis and the infertile women with endome-
triosis were previously described [15]. During laparoscopy, 
we observed the condition of the pelvic cavity, uterus, fal-
lopian tubes, ovaries, tubo-ovarian relationship, status of 
the Pounch of Douglas, and fimbrie. The inclusion criteria 
for the fertile control women were: regular menses, mobility 
of uterus, no anatomical changes in the reproductive tract, 
no hormonal treatments, and at least one child born no 
more than one year before the study (Tab. 1). The exclusion 
criteria were: signs of past or present inflammation.  We 
didn’t find inflamed fallopian tubes. In each patient, the pe-
ritoneal fluid was sampled for bacteriological examination, 
and was found to be sterile. Exclusion criteria also included 
pelvic abnormalities such as uterine fibroids, ovarian cysts, 
hydrosalpinges, adhesions in pouch of Douglas and the 
rest of the pelvis, endometriosis, adenomyosis, polycystic 
ovary syndrome (PCOS) or any other benign or malignant 
gynaecological diseases.
Patients with endometriosis were evaluated according 
to the revised American Society for Reproductive Medicine 
(rASRM) classification system [16] (Tab. 1). The inclusion crite-
ria for infertile women with diagnosed endometriosis were: 
regular menses, no anatomical changes in the reproductive 
tract, no hormonal treatments and a minimum of one year of 
Table 1. Clinical characteristics of women with endometriosis and controls
Proliferative phase
Characteristic I+II stage of endometriosisb III+IV stage of endometriosisb Fertile Woman
Numbers 10 10 9
Age (years) 36.5 (25–39)a 36 (27–40) 34 (27–36)a
Parity NA NA 1 (1–2)a
Duration of infertility (years) 2 (1–4)a 2 (2–3)a NA
Luteal phase
Characteristic I+II stage of endometriosisb III+IV stage of endometriosisb Fertile Woman
Numbers 8 7 8
Age (years) 35 (27–38)a 35 (25–41) 34 (28–40)a
Parity NA NA 1 (1–3)a
Duration of infertility (years) 3 (1–4)a 3 (1–5)a NA
Median a(Range), revised American Society for Reproductive Medicine classification b(rASRM) [16]; NA — not applicable
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infertility with a current desire for conception. The exclusion 
criteria were: mechanical distortion of the endometrial cavity 
by fibroids, bilateral tubal occlusion, male factor infertility, 
adenomyosis, PCOS or benign or malignant gynaecologi-
cal diseases. All included patients with endometriosis had 
laparoscopic and histological diagnosis of endometriotic 
lesions. The patients with endometriosis and the healthy 
controls were all Caucasian race of Polish ancestry (Tab. 1). 
Samples were obtained by Pipelle or hysteroscopic biop-
sy of the eutopic endometrium during either the middle 
follicular or the middle luteal phase based on endometrial 
dating criteria [17]. Samples of mid-luteal eutopic endo-
metrium tissue from patients and controls were collected 
during the implantation window, i.e., 7–9 days after ul-
trasound-confirmed ovulation. The eutopic endometrium 
samples were then used for total RNA and protein isolation.
Reverse transcription and quantitative real-time 
PCR (RT-QPCR) analysis of HSD3B2, HSD17B1, 
HSD17B2, ESR1, ESR2 and AR transcript levels
The obtained endometrial samples were placed over-
night in Allprotect Tissue Reagent Solution (Qiagen GmbH, 
Hilden, Germany) and frozen until extraction. Isolation of 
total RNA containing cytoplasmic mRNA was conducted 
with the use of the AllPrep DNA/RNA/Protein Mini Kit (Qia-
gen GmbH, Hilden, Germany). For total RNA isolation we 
used, according to the manufacturer recommendation, 
an additional RNase-Free Dnase I Set (Qiagen GmbH, Hilden, 
Germany) to eliminate the risk of DNA contamination. RNA 
quality was determined spectrophotometrically using 
a NanoDrop ND1000 (Thermo Fisher Scientific, Waltham, 
MA) and agarose gel electrophoresis. RNA samples were 
reverse-transcribed (RT) into complementary DNA (cDNA) 
with the Quanti-Tect Reverse Transcription Kit (Qiagen 
GmbH, Hilden, Germany) (Tab. 2). 
Quantitative analysis of HSD3B2, HSD17B1, HSD17B2, 
ESR1 ESR2 and AR cDNAs (Tab. 2) was performed by the 
Rotor-Gene 3000 thermocycler (Corbett Research, Australia), 
using SYBR Green I as the detection dye. HSD3B2, HSD17B1, 
HSD17B2, ESR1 ESR2 and AR cDNAs were quantified using 
the relative quantification method with a calibrator. The cali-
brator was prepared with a cDNA mix from all cDNA samples, 
and consecutive dilutions were used to create a standard 
curve. For amplification, 1 μl of the cDNA solution was added 
to 19 μl of the DyNAmo HS SYBR Green qPCR Kit (Thermo 
Fisher Scientific, Waltham, MA) and primers mix (Tab. 2). 
Table 2. Detailed RT-qPCR procedure
Definition of experimental and control groups
Experimental group includes  eutopic, proliferative and luteal endometrium from 
infertile women with various stages of endometriosis defined according with revised 
American Society for Reproductive Medicine (rASRM) classification system. Control 
group includes eutopic, proliferative and luteal endometrium from fertile women 
w/o endometriosis
Number within each group
Proliferative endometrium has 12 samples with minimal endometriosis (I, II st. rASRM), 
11 samples with advanced endometriosis (III–IV st. RASRM) and 9 samples from fertile 
women w/o endometriosis
Luteal endometrium has 8 samples with minimal endometriosis (I, II st. rASRM), 7 samples 
with advanced endometriosis (III- IV st. RASRM) and 9 samples from fertile women 
w/o endometriosis 
Acknowledgment of authors’ contributions Przemysław Wirstlein
Description Eutopic endometrium tissue
Processing procedure Immersed overnight  in AllProtect Tissue Reagent (Qiagen, Germany)
If frozen, how and how quickly? Frozen –20°C
Sample storage conditions and duration (especially 
for FFPEb samples) –20°C
Procedure and/or instrumentation Affinity, on columns
Name of kit and details of any modifications 
AllPrep® DNA/RNA/Protein/ MiniKit (50) ref. # 80004. In last step, protein  was precipitated 
with ice cold acetone, and resolved in 2% SDS, according to Pierce TR0049.0 technical 
resouce
Source of additional reagents used SDS obtained from Sigma Aldrich (Steinheim, Germany)
Details of DNase or RNase treatment RNA samples were treated with DNase I
Contamination assessment (DNA or RNA) qPCR amplification of genomic DNA fragment
Nucleic acid quantification spectrophotometrically
Instrument and method NanoDrop ND1000 (ThermoScientific, USA)
RNA integrity: method/instrument agarose gel electrophoresis
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Table 2. (cont.) Detailed RT-qPCR procedure
Inhibition testing (Cq dilutions, spike, or other) Cq dilutions of cDNA
Complete reaction conditions 
1ug of Total RNA was dissolved in  14ul final volume gDNA wipeout Buffer. After gDNA 
eliminaton step (2 min; 420C). Next, 4µl Quantiscript RT Buffer (IncludesMg and dNTPs ), 1 µl 
Primer Mix (blended: oligo d(T) and hexamers) and 1µl Quantiscript Reverse Transcriptase 
(Contained Rnase inhibitor) was added to final  volume 20 µl). Reverse transcription was 
performed 15 min. at 420C and 3 min. at 950C
Amount of RNA and reaction volume 1 μg of RNA, reaction volume 20 μl
Priming oligonucleotide (if using GSP) and 
concentration 
oligo d(T) and hexamers  blended
The manufacturer didn’t provaide detailed concentration
Reverse transcriptase and concentration Quantiscript Reverse Transcriptase (Qiagen, Germany). The manufacturer didn’t provaide details 
Temperature and time according to the manufacturer’s protocol 
Manufacturer of reagents and catalogue numbers For RT Quantitect Reverse Transcription Kit, ref. # 205311(Qiagen, Germany)
Storage conditions of cDNA –20°C
Gene symbol HSD3B2, HSD17B1, HSD17B2, ESR1, ESR2, AR, 
Sequence accession number (ENST)
00000543831 HSD3B2
00000585807 HSD17B1
00000199936 HSD17B2
00000440973 ESR1 
00000554572 ESR2
00000374690 AR
Amplicon length 
127 HSD3B2
178 HSD17B1
181 HSD17B2 
153 ESR1 
166 ESR2
138  AR  
In silico specificity screen (BLAST, and so on) BLASTN 2.5.1+ (https://blast.ncbi.nlm.nih.gov/)
Sequence alignment BLASTN 2.5.1+ (https://blast.ncbi.nlm.nih.gov/)
Secondary structure analysis of amplicon Oligo 7.6 software (http://www.oligo.net/downloads.html)
Location of each primer by exon or intron (if 
applicable) 
HSDB2: forward — exon 4, reverse — exon 4
HSD17B1: forward — exon 4, reverse — exon 5
HSD17B2: forward — exons junction1/2, reverse — exon 2
ESR1: forward — exon 9, reverse — exon 9
ESR2: forward — exon 8, reverse — exon 9
AR: forward — exon 7, reverse — exon 7
What splice variants are targeted? 
HSD3B2-206
HSD17B1-202
HSD17B1-201
ESR1-207
ESR1-208
AR-201
Primer sequences 
HSD3B2 forward: 5’GCGGCTAATGGGTGGAATCTA 3’
HSD17B1 forward: 5’CGAAGGCTTATGCGAGAGTC 3’
HSD17B2 forward: 5’CTGGTGACAGGTGGTGATTG 3’
ESR1 forward: 5’ AGCACCCTGAAGTCTCTGGA 3’
ESR2 forward: 5’ TGGAGTCTGGTCGTGTGAAGA 3’
AR forward: 5’ CAGTGGATGGGCTGAAAAAT 3’
HSD3B2 reverse: 5’CATTCTTGTTCAGGGCCTCAT 3’
HSD17B1 reverse: 5’GTGGGCGAGGTATTGGTAGA 3’
HSD17B2 reverse: 5’TTATCTGCACTGGCTTCGTG 3’
ESR1 forward: 5’ GATGTGGGAGAGGATGAGGA 3’
ESR2 forward: 5’ CTTCACCATTCCCACTTCGT 3’
AR forward: 5’ GGAGCTTGGTGAGCTGGTAG 3’
ACTB forward: 5’TCCTCCCTGGAGAAGAGCTCAC3’
ACTB reverse: 5’TGAAGGTAGTTTCGTGGATGC3’
RPLP0 forward: 5’GGCGACCTGGAAGTCCAACT3’
RPLP0 reverse: 5’CCATCAGCACCACAGCCTTC3’
Manufacturer of oligonucleotides TIB MOLBIOL Sp. z o.o.(Poznan, Poland; http://www.tib-molbiol.pl/)
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Table 2. (cont.) Detailed RT-qPCR procedure
Purification method  Polyacrylamide gel electrophoresis
Complete reaction conditions 10 μl Master Mix (2×conc., 5 mM MgCl2incl.) + + 1μl  F and R primer mix (5 μM final conc. of each one) + 1 μl cDNA + 8 μl H2O
Reaction volume and amount of cDNA/DNA Reaction volume 20 μl (cDNA 1 μl)
Primer, (probe), Mg2+, and dNTP concentrations Final concentrations: Primer 0.5 μM, Mg2+ 2.5 mM, dNTP 0.8 mM 
Polymerase identity and concentration  Polymerase based on a hot start version of a modified Tbr DNA polymerase. 
Buffer/kit identity and manufacturer DyNAmoTM HS SYBR®Green qPCR Kit Ref.#F-410 (ThermoScientific, USA)
Additives (SYBR Green I, DMSO, and so forth) SYBR Green I
Manufacturer of plates/tubes and catalog number ThermoScientific 0,2 PCR Thermo-Tubes Ref.#AB-0620
Complete thermocycling parameters 
Preincubation: 15 min 95°C, 
Amplification: 10s 94°C, 10s 55–60°C, 20s 72°C with single fluorescence acquisition, 
40 cycles, Ramp rate: 2.2°C (cooling) and 4.4°C (heating) Melting: 1 min 95°C, 1 min 40°C, 
75–95°C with continuous fluorescence acquisition
Reaction setup (manual/robotic) Manual
Manufacturer of qPCR instrument RotorGene3000 (Corbett Research, Australia)
Evidence of optimization (from gradients) PCR with gradient temperature of annealing and electrophoresis
Specificity (gel, sequence, melt, or digest) Melting curve
For SYBR Green I, Cq of the NTC NTC with no amplification observed (Cq > 32)
Calibration curves with slope and y intercept The PCR amplification efficiency for target and reference cDNA was determined by different standard curves created by consecutive dilutions of the cDNA template mixture
PCR efficiency calculated from slope 
HSD3B2 E =1.000
HSD17B1-E = 0.999
HSD17B1-2E = 0.999
ESR1-E = 1.000
ESR1-E = 0.998
AR-E = 0.996
r2 of calibration curve R2 range from 0.9985 to 0.9997
Linear dynamic range cDNA dilution from 1 to 1/10–4
qPCR analysis program (source, version) RotorGene 6. Version 6.1 (Build 93) (Corbett Research, Australia) 
Method of Cq determination Second derivative maximum method
Outlier identification and disposition  Pierce criterion
Results for NTCs No amplification observed for NTCs
Justification of number and choice of reference 
genes 
Two reference genes: Actin, beta (ACTB) and Ribosomal Protein Lateral Stalk Subunit 
P0 (RPLP0)
Description of normalization method 
Relative quantification method with a calibrator. The calibrator was prepared as a cDNA mix 
from all cDNA samples and consecutive dilutions were used to create a standard curve. The 
quantity of studied transcript in each sample was standardized by the geometric mean of 
transcript levels
Number and stage (reverse transcription or qPCR) of 
technical replicates Three
Statistical methods for results significance the Kruskal-Wallis test with Dunn’s post-hoc
Software (source, version)  SigmaStat v.3.5 (Systat Software Inc; USA)
The HSD3B2, HSD17B1, HSD17B2, ESR1 ESR2 and AR 
transcript levels in each sample were standardized by the 
geometric means of the reference beta-actin (ACTB) and 
ribosomal protein stalk subunit P0 (RPLP0) transcript lev-
els. The PCR amplification efficiency for the target and ref-
erence cDNA was determined by different standard curves 
created by consecutive dilutions of the cDNA template mix-
ture. The HSD3B2, HSD17B1, HSD17B2, ESR1 ESR2 and AR 
cDNA and ACTB and RPLP0 cDNAs were amplified using the 
primer pairs presented in Table 2. The HSD3B2, HSD17B1, 
HSD17B2, ESR1 ESR2 and AR mRNA levels were expressed as 
multiples of these cDNA concentrations in the calibrator. The 
Y axis presents relative quantity (RQ) of HSD3B2, HSD17B1, 
HSD17B2, ESR1 ESR2 and AR mRNA levels. 
Data analysis
Statistical analyses were conducted using the Mann-
-Whitney rank sum test and the Kruskal-Wallis one-way 
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ANOVA on ranks. Statistical analyses were conducted using 
Statistica version 10, 2011 (Stat Soft, Inc., Tulsa, USA). 
Ethics
The study was conducted in accordance with the code 
of ethics of the Declaration of Helsinki and obtained the ap-
proval of the Local Ethical Committee of Poznan University 
of Medical Sciences (923/14/04.12.2014). Written informed 
consent was obtained from all participating individuals.
RESULTS
Comparison of HSD3B2, HSD17B1, HSD17B2, 
ESR1, ESR2 and AR transcript levels  
in the mid-follicular eutopic endometrium 
between infertile women with endometriosis 
and fertile women
The biopsy of eutopic endometrium was performed 
during the mid-follicular phase in 10 infertile women with 
endometriosis at I/II severity stage and 10 infertile women 
with III/IV severity stage. The biopsy of eutopic endometrium 
was also performed in 9 healthy fertile women during the 
mid-follicular phase (Tab. 1). 
In the mid-follicular eutopic endometrium, we obse-
rved a significant increase in HSD3B2 transcript levels in 
all infertile women with endometriosis (p = 0.003) and in 
patients with stage I/II endometriosis (p = 0.008) and stage 
III/IV endometriosis (p = 0.009) compared to the levels in all 
fertile women (Fig. 1A). There were no significant differences 
in HSD17B1 transcript levels between all infertile women 
with endometriosis (p = 0.899), subgroups with stages I/II 
endometriosis (p = 0.222) and stages III/IV endometriosis 
(p = 0.625) and fertile women (Fig. 1B). We found an incre-
asing trend in HSD17B2 transcript levels, which was not 
statistically significant, in the mid-follicular eutopic endome-
trium in all infertile women with endometriosis (p = 0.071). 
We found a significantly increased HSD17B2 transcript level 
in the subgroup of patients with stages I/II endometriosis 
(p = 0.029) but not in the stages III/IV subgroup (p = 0.351) 
(Fig. 1C). We observed a significant increase in ESR1 trans-
cript levels in all infertile women with endometriosis 
(p = 0.008), those with stages I/II endometriosis (p = 0.019) 
and those with stages III/IV endometriosis (p = 0.023) com-
pared to the level in all fertile women (Fig. 1D). There was no 
significant increasing trend of ESR2 transcript levels in the 
mid-follicular eutopic endometrium in all infertile women 
(p = 0.079) with endometriosis, or in subgroups with stages 
I/II (p = 0.056) and III/IV (p = 0.261) compared to the levels 
in fertile women (Fig. 1E). We did not find significant diffe-
rences in AR transcript levels between all infertile women 
with endometriosis (p = 0.461) or subgroups with stages I/II 
(p = 0.450) and III/IV (p = 0.635) and fertile women (Fig. 1F). 
Comparison of HSD3B2, HSD17B1, HSD17B2, 
ESR1, ESR2 and AR transcript levels  
in the mid-luteal eutopic endometrium  
between infertile women with endometriosis  
and fertile women
The biopsy of eutopic endometrium was performed 
during the mid-luteal phase in 8 infertile women with en-
dometriosis at I/II severity stage and 7 with III/IV severity 
stage. The biopsy of eutopic endometrium was also was 
performed in 8 healthy fertile women during the mid-luteal 
phase (Tab. 1). 
In the mid-luteal eutopic endometrium, we found a sta-
tistically insignificant increasing trend of HSD3B2 transcript 
levels in all infertile women with endometriosis (p = 0.057) 
and in the subgroups with stages I/II (p = 0.055) but not in 
the subgroup with stages III/IV (p = 0.225) when compared 
to the levels in fertile women (Fig. 2A). There were no signi-
ficant differences between fertile women and all infertile 
women with endometriosis, the subgroup with stages I/II 
and the subgroup with stages III/IV for transcript levels of 
HSD17B1 (p = 0.751, p = 0.609, p = 0.943 respectively), 
HSD17B2 (p = 0.812, p = 0.798, p = 0.937, respectively), 
ESR1 (p = 0.692, p = 0.523, p = 0.134, respectively) and 
ESR2 (p = 0.478, p = 0.250, p = 0.957, respectively), or AR 
(p = 0.937, p = 0.999, p = 0.830, respectively) (Fig. 2B–2F). 
DISCUSSION
Endometriosis is an estrogen-influenced gynaecologi-
cal disorder characterized by over-activity of the estrogen 
pathway, including increased production of 17-bestradiol 
(E2) and its action in the eutopic and ectopic endometrium. 
HSD3B catalyses the oxidation and isomerization of 
d-5-3-beta-hydroxysteroid precursors into delta-4-ketoste-
roids resulting in the formation of all classes of steroids. The 
HSD3B also converts epiandrosterone, to 5α-androstan-3-
-one. HSD3B1 is expressed predominantly in the placenta 
and the skin, whereas HSD3B2 is expressed almost exclusi-
vely in the adrenal glands and the gonads [18]. To date there 
have been several studies that evaluated HSD3B2 expression 
in endometriosis [10–12]. Attar et al. (2009) demonstrated 
that HSD3B2 transcript levels are significantly upregulated 
in extraovarian (peritoneal) endometriotic tissues compa-
red to eutopic endometrial tissue from endometriosis-free 
women [10]. 
It has also been found that interleukin-4 and prostaglan-
din E2 synergistically increased HSD3B2 transcript levels 
in endometrioma stromal cells [11]. Recently, Huhtinen et 
al. (2014) found significantly increased HSD3B2 transcript 
levels in extraovarian and ovarian endometriosis lesions 
compared to control eutopic endometrium in the luteal or 
follicular phase. In contrast, Huhtinen et al. (2011) have not 
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Figure 1. Comparison of HSD3B2 (A), HSD17B1 (B), HSD17B2 (C), ESR1 (D), ESR2 (E) and AR (F) transcript levels in the mid-follicular eutopic 
endometrium between fertile women and all infertile women with endometriosis, those with stages I/II endometriosis, and those with stages III/IV 
endometriosis. 
Frozen tissue was homogenized, followed by total RNA isolation. Quantitative analyses of transcript levels were performed by RT-qPCR using  
the SYBR Green I system. The HSD3B2, HSD17B1, HSD17B2, ESR1, ESR2 and AR transcript levels in each sample were standardized by the geometric 
mean of references using ACTB and RPLP0 cDNA levels. The P value was evaluated by the Mann-Whitney rank sum test and the Kruskal-Wallis test 
with pairwise multiple comparisons and post hoc Dunn’s test. The boxes and the middle lines correspond to the values from the lower to upper 
quartiles and the medians, respectively. RQ-relative quantity
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Figure 2. Comparison of HSD3B2 (A), HSD17B2 (B), HSD17B2 (C), ESR1 (D), ESR2 (E) and AR (F) transcript levels in the mid-luteal eutopic 
endometrium between fertile women and all infertile women with endometriosis, those with stages I/II endometriosis and those with stages III/IV 
endometriosis. 
Frozen tissue was homogenized, followed by total RNA isolation. Quantitative analyses of transcript levels were performed by RT-qPCR using  
the SYBR Green I system. The HSD3B2, HSD17B1, HSD17B2, ESR1, ESR2 and AR transcript levels in each sample were standardized by the geometric 
mean of references using ACTB and RPLP0 cDNA levels. The P value was evaluated by the Mann-Whitney rank sum test and the Kruskal-Wallis test 
with pairwise multiple comparisons and post hoc Dunn’s test. The boxes and the middle lines correspond to the values from the lower to upper 
quartiles and the medians, respectively. RQ-relative quantity
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found any differences in HSD3B2 transcript levels between 
luteal and follicular phase eutopic endometrium from wo-
men with endometriosis and the eutopic endometrium of 
healthy women [12]. 
In our studies we found significantly increased levels of 
HSD3B2 transcript in the mid-follicular eutopic endometrium 
from all infertile women with endometriosis and in subgroups 
with stages I/II and III/IV when compared to the transcript 
levels in healthy women. In contrast, in the mid-luteal phase, 
there was no significant increasing trend of HSD3B2 trans-
cripts in all infertile women with endometriosis or in the 
subgroup with stages I/II versus the levels in the controls. 
The presence of HSD17B1 and HSD17B2 oxidoreduc-
tases has been demonstrated in the eutopic endometrium 
[13]. HSD17B1 oxidizes estrone (E1) to E2, which is a more 
biologically active estrogen, while HSD17B2 reduces E2 to 
E1 [19]. Smuc et al. (2007) reported significantly increased 
HSD17B1 transcript levels in ectopic ovarian endometriosis 
compared to the levels in normal eutopic endometrium 
[13]. Delvoux et al. (2013) demonstrated that inhibition of 
HSD17B1 can potentially be used as a treatment to restore 
the correct metabolism of estrogen in women with endome-
triosis with elevated local HSD17B1 activity [19]. However, in 
our study we did not find differences in HSD17B1 transcript 
levels between the eutopic endometrium of fertile women 
and that of infertile women with endometriosis. 
Expression of HSD17B2 in the luteal phase is upregu-
lated by progesterone in the endometrial glandular cells 
converting E2 to E1, the less biologically active estrogen 
[20]. Deficiency of the HSD17B2 enzyme impairs the inacti-
vation of E2 to E1, which favours the accumulation of E2 in 
endometriosis [21]. Zeitoun et al. (1998) demonstrated the 
presence of HSD17B2 transcripts and proteins in the luteal 
eutopic endometrium of healthy women but not in the lu-
teal samples of endometriotic lesions [22]. Smuc et al. (2007) 
reported significantly decreased HSD17B2 transcript levels 
in ectopic ovarian endometriosis compared to normal endo-
metrium [13] and HSD17B2 deficiency and locally increased 
E2 levels in ectopic implants in endometriosis [23]. In our 
studies, we found a statistically insignificant increasing trend 
of HSD17B2 transcript levels in the eutopic endometrium 
during the follicular phase but not in the luteal phase. 
The estrogen receptor exists in two isoforms: ESR1 and 
ESR2 [24–25] with a 56% homology between them [26]. ER 
activity depends on the binding of E2 and the nuclear recep-
tor-induced transcription of ER-regulated genes. Research 
in the murine model has demonstrated that ESR1 plays 
the primary role in the uterus and neuroendocrine system, 
and female mice lacking ESR1 are infertile because of im-
paired ovarian and uterine function, while those lacking 
ESR2 display ovarian defects and subfertility [27]. The abnor-
mal expression of ESR1 has been reported in endometriosis 
[13, 28, 29]. Smuc et al. (2007) demonstrated that ESR1 tran-
script levels were downregulated in women with endometri-
osis group compared to the levels in the control group [13]. 
Using chromatin immunoprecipitation analysis, Monteiro et 
al. (2012) revealed the hypoacetylation of H3/H4 histones 
inside the ESR1 promoter in endometriosis lesions but not 
in the control eutopic endometrium [28]. This hypoacety-
lation of H3/H4 accounted for reduced ESR1 expression in 
endometriosis lesions versus control eutopic endometrium 
[28]. Recently, Khan et al. (2017) suggested dysregulation of 
ESR1 expression as one of the significant causative factors 
in the pathogenesis of ovarian endometriosis [29] In our 
studies, we observed a significant increase in ESR1 tran-
script levels in the follicular but not the luteal phase in all 
infertile women with endometriosis and in the subgroups 
with stages I/II and stages III/IV. 
The knowledge of biologic roles of ESR2 in the endo-
metrium and in endometriosis is still elusive [30]. Smuc et 
al. (2007) demonstrated that ESR2 transcript levels were 
upregulated in the endometriosis group versus the control 
group [13]. An ESR2-selective compound has been demon-
strated to have therapeutic activity in a rodent endometrio-
sis model [30]. Our study only demonstrated an insignificant 
increase in ESR2 transcript levels in the mid-follicular eutopic 
endometrium in all infertile women with endometriosis and 
in the subgroup with stages I/II. 
To date, AR gene CAG repeat polymorphisms have been 
associated with an increased risk for mild endometriosis 
[31]. However, our results did not reveal any significant 
changes in the expression of AR in the proliferative and 
luteal phases between infertile women with endometriosis 
and fertile women. 
The differences between our results and others in terms 
of expression might be due to the employment of ectopic 
implants, despite the eutopic endometrium of endome-
triosis. Studies usually compare the expression of genes 
encoding proteins involved in estrogen activity in ectopic 
implants of endometriosis independent of the menstrual 
cycle phases [10–13, 22, 23, 28, 29]. We conducted our study 
using primary eutopic endometrium consisting of a mix of 
uterine gland, columnar epithelium and stromal fibroblast 
cells. Our study was also conducted in selected infertile 
women with endometriosis with determined menstrual 
phase cycles. However, our study has limitations with the 
very small number of studied cases and needs further eva-
luation of proteins using either immunohistochemistry or 
western blot. 
CONCLUSIONS
Observed significant increase in HSD3B2 and ESR1 trans-
cripts in follicular eutopic endometrium from infertile 
women with endometriosis may be related to abnormal 
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biological effect of E2 in endometrium, further affecting the 
development of human embryos.
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